Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Overview
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Companies Involved in Therapeutics Development
Cellmid Ltd
Ribomic Inc
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Drug Profiles
CAB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iMDK - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Midkine for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Dormant Products
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Product Development Milestones
Featured News & Press Releases
Aug 22, 2019: Patent for improved Midkine antibody allowed in Europe
Sep 12, 2018: Cellmid’s lead antibody effective in rare chronic kidney disease
Feb 07, 2017: Cellmid’s European Midkine Patent For Alopecia Allowed
Jan 18, 2017: Cellmid Receives Australian Government Grant For Midkine Programme
Oct 05, 2016: Cellmid’s Midkine Antibodies Show Anti-Tumour Activity against Brain Cancer
Jun 23, 2015: Cellmid Collaboration To Treat Brain Cancer
Jun 15, 2015: Cellmid’S Humanised Midkine Antibody Drug Is Safe In Toxicology Studies
Jul 15, 2014: Cellmid Granted UK Patent for Use of Midkine for Hair Growth
Oct 06, 2011: Cellmid Completes Humanization Of Anti-midkine Antibody In Collaboration With Antitope
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Cellmid Ltd, H1 2020
Pipeline by Ribomic Inc, H1 2020
Dormant Projects, H1 2020